RGD Peptide Boosts Anti-PD-L1 Immunotherapy by Helping It Penetrate Liver Tumors
Co-administered internalizing RGD peptide enhanced anti-PD-L1 therapy in HCC by improving antibody tumor penetration, increasing T cell infiltration, and overcoming the immunosuppressive microenvironment.
Quick Facts
What This Study Found
Co-administered iRGD peptide enhanced anti-PD-L1 therapy in HCC: improved antibody tumor penetration, increased T cell infiltration, overcame immunosuppressive TME, and significantly outperformed anti-PD-L1 alone.
Key Numbers
How They Did This
HCC mouse models treated with anti-PD-L1 ± internalizing RGD peptide, with tumor penetration, T cell infiltration, TME analysis, and tumor growth assessment.
Why This Research Matters
Most liver cancer patients don't respond to immunotherapy because the drug can't penetrate the tumor. A simple peptide co-infusion could change this.
The Bigger Picture
Peptide-enhanced tumor penetration could be a general strategy to improve immunotherapy across solid tumors that resist checkpoint inhibitors.
What This Study Doesn't Tell Us
Mouse models. Human HCC is heterogeneous. iRGD manufacturing and dosing in humans not optimized.
Questions This Raises
- ?Would iRGD enhance immunotherapy for other solid tumor types?
- ?Is the effect dose-dependent?
- ?Could iRGD be combined with other checkpoint inhibitors (anti-PD-1, anti-CTLA-4)?
Trust & Context
- Key Stat:
- Peptide unlocks immunotherapy A simple co-administered RGD peptide enabled anti-PD-L1 antibody to penetrate liver tumors, overcoming the main reason immunotherapy fails in HCC
- Evidence Grade:
- Comprehensive preclinical with multi-model validation.
- Study Age:
- Published in 2025.
- Original Title:
- Co-administered internalizing RGD peptide boosts anti-PD-L1 therapy in hepatocellular carcinoma.
- Published In:
- JHEP reports : innovation in hepatology, 8(3), 101731 (2026)
- Authors:
- Klug, Jan Henrik, Aliraj, Blerina, Alcober-Boquet, Lucia, Denk, Dominic, Germann, Lena, Meindl-Beinker, Nadja M, De La Torre, Carolina, Waidmann, Oliver, Finkelmeier, Fabian, Zeuzem, Stefan, Brüne, Bernhard, Vogl, Thomas J, Weigert, Andreas, Piiper, Albrecht
- Database ID:
- RPEP-15444
Evidence Hierarchy
Frequently Asked Questions
Why doesn't immunotherapy work for many liver cancers?
The antibody drug can't penetrate deep into solid liver tumors. The iRGD peptide creates pathways through the tumor, allowing the antibody and immune cells to reach cancer cells they couldn't access before.
How simple is adding the peptide?
Very simple — it's co-infused with the existing immunotherapy drug. No new equipment or procedures needed, just adding a peptide to the IV infusion.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-15444APA
Klug, Jan Henrik; Aliraj, Blerina; Alcober-Boquet, Lucia; Denk, Dominic; Germann, Lena; Meindl-Beinker, Nadja M; De La Torre, Carolina; Waidmann, Oliver; Finkelmeier, Fabian; Zeuzem, Stefan; Brüne, Bernhard; Vogl, Thomas J; Weigert, Andreas; Piiper, Albrecht. (2026). Co-administered internalizing RGD peptide boosts anti-PD-L1 therapy in hepatocellular carcinoma.. JHEP reports : innovation in hepatology, 8(3), 101731. https://doi.org/10.1016/j.jhepr.2026.101731
MLA
Klug, Jan Henrik, et al. "Co-administered internalizing RGD peptide boosts anti-PD-L1 therapy in hepatocellular carcinoma.." JHEP reports : innovation in hepatology, 2026. https://doi.org/10.1016/j.jhepr.2026.101731
RethinkPeptides
RethinkPeptides Research Database. "Co-administered internalizing RGD peptide boosts anti-PD-L1 ..." RPEP-15444. Retrieved from https://rethinkpeptides.com/research/klug-2026-coadministered-internalizing-rgd-peptide
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.